Pembrolizumab for primary malignant melanoma of the central nervous system

J Neurooncol. 2018 Aug;139(1):225-227. doi: 10.1007/s11060-018-2848-y. Epub 2018 Apr 2.

Authors

Chakib El Habnouni¹, Claire Bléchet², Guido Bens³

Affiliations

¹ Department of Dermatology, Centre hospitalier Régional Orléans La Source, 14 Avenue de l'Hôpital, CS 86709, 45067, Orléans Cedex 2, France. [email protected].
² Department of Pathology, Centre hospitalier Régional Orléans La Source, 14 Avenue de l'Hôpital, CS 86709, 45067, Orléans Cedex 2, France.
³ Department of Dermatology, Centre hospitalier Régional Orléans La Source, 14 Avenue de l'Hôpital, CS 86709, 45067, Orléans Cedex 2, France.

PMID: 29611049
DOI: 10.1007/s11060-018-2848-y

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Disease Progression
Female
Humans
Melanoma / diagnostic imaging
Melanoma / drug therapy*
Melanoma / surgery
Meningeal Neoplasms / diagnostic imaging
Meningeal Neoplasms / drug therapy*
Meningeal Neoplasms / surgery
Middle Aged
Neoplasm Recurrence, Local / diagnostic imaging
Neoplasm Recurrence, Local / drug therapy
Treatment Failure

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab